(MedPage Today) -- Only one person has developed a new HIV infection during a year-long extension of the landmark PURPOSE 1 and PURPOSE 2 trials testing twice-yearly injectable lenacapavir (Yeztugo) for pre-exposure prophylaxis (PrEP), according...
Long-Acting Lenacapavir Still Delivered Effective HIV PrEP After a Year
